Overview
Lanabecestat is under investigation in clinical trial NCT03499041 (A Study of LY3314814 in Participants With Liver Impairment).
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
Lanabecestat (AZD3293/LY3314814): A Clinical and Scientific Postmortem of a BACE1 Inhibitor for Alzheimer's Disease
Executive Summary
Lanabecestat, a small molecule developed under the codes AZD3293 and LY3314814, represents one of the most advanced and scientifically compelling drug candidates to emerge from the therapeutic strategy of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibition.[1] Co-developed by AstraZeneca and Eli Lilly and Company, this orally available, brain-penetrant compound was designed as a potential disease-modifying therapy for Alzheimer's disease (AD).[4] Its mechanism was rooted in the amyloid cascade hypothesis, which posits that the accumulation of amyloid-beta (
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2018/06/04 | Phase 1 | Withdrawn | |||
2018/04/24 | Phase 1 | Withdrawn | |||
2018/04/17 | Phase 1 | Withdrawn | |||
2017/07/19 | Phase 1 | Completed | |||
2017/01/12 | Phase 1 | Completed | |||
2016/11/23 | Phase 3 | Terminated | |||
2016/05/26 | Phase 3 | Terminated | |||
2016/01/26 | Phase 1 | Completed | |||
2015/10/05 | Phase 1 | Completed | |||
2015/09/04 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.